Biotech VC Funds

Koch Disruptive Technologies is an investment firm that partners with entrepreneurs building transformative companies across various industries. Established as a subsidiary of Koch Industries, KDT aims to drive societal and economic impact by investing in high-growth potential businesses that are aligned with Koch's long-term vision and values. KDT's investment strategy is centered around the concept of "creative destruction," promoting continuous improvement and innovation even at the expense of existing business models. The firm is stage-agnostic, investing in companies at various stages of their life cycle, from seed to late-stage growth. Key sectors of focus include healthcare, supply chain and manufacturing, cybersecurity, semiconductors, connectivity, fintech, enterprise software, and energy transformation. KDT provides its portfolio companies with more than just capital. Through Koch Labs®, they offer access to a vast network of resources, expertise, and capabilities across Koch Industries’ global ecosystem, which includes over 120,000 employees in 60+ countries. This network helps accelerate growth and enhances the value of their portfolio companies. Notable investments by KDT include SHINE, a nuclear technology company; Deepcell, which focuses on AI-powered single-cell analysis; and Via, a transit-tech startup. The firm is led by Chase Koch and a team of experienced professionals dedicated to supporting disruptive innovation.

KohFounders is a Los Angeles-based pre-seed venture capital firm founded in 2014, specializing in supporting emerging ecosystems and early-stage technology startups. The firm focuses on industries such as healthcare tech, fintech, edtech, agtech, and frontier tech, targeting mission-driven founders who are building scalable and impactful businesses. KohFounders is known for taking a hands-on approach, helping entrepreneurs before they raise institutional capital. With a diverse portfolio, KohFounders has backed notable companies like K Health, a unicorn in the healthcare technology space, as well as Wellth, Starfish Space, and Andrena, which operates in the internet service sector. The firm has also seen several successful exits, including SimpleHealth and Amobee, highlighting its focus on high-growth companies with strong market potential. Led by Founding Partner Bong Koh, who brings extensive experience from previous roles at companies like Photobucket and Brand Networks, KohFounders provides more than just capital—offering mentorship, strategic guidance, and access to a wide network. The team works closely with founders to scale their businesses and achieve long-term success.

Kombo Ventures is a diversified investment and holding company founded by Kevin Gould, specializing in consumer brands, technology, and entertainment. With a focus on launching and scaling direct-to-consumer businesses, Kombo Ventures has co-founded high-growth brands like Glamnetic, a top press-on nail and magnetic eyelash company, and INH Hair, a hair extensions brand, both of which have gained significant traction in the beauty industry. These brands have generated impressive revenues and secured distribution deals with major retailers like Sephora, Ulta, and Target. In addition to launching new ventures, Kombo Ventures also acquires and scales existing brands, utilizing its best-in-class infrastructure to help businesses reach new heights. The company is known for identifying emerging trends and leveraging its extensive network in the digital creator and e-commerce spaces to create defensible business models. Through its AngelList syndicate, Kombo provides access to exclusive deal flow for its limited partners, deploying millions in investments across various industries. Kombo’s notable investments and exits include Gyft (acquired by First Data), Whistle (acquired by Mars), and Draft Kings, which went public. Kombo Ventures also operates in the entertainment industry, managing talent and helping creators build long-term growth through business ventures. With its deep expertise in digital marketing and consumer behavior, Kombo Ventures is strategically positioned to continue building and investing in the next wave of influential brands in the digital and consumer sectors. This forward-thinking approach has made the firm a key player in both the venture capital and entertainment spaces.

Kompas VC is an early-stage venture capital firm that focuses on investing in technologies that drive digital transformation and decarbonization within the building and manufacturing industries. Established in 2021, Kompas VC has offices in Amsterdam, Berlin, Copenhagen, and Tel Aviv. The firm typically invests between €1 million and €5 million in Seed and Series A rounds, continuing to support its portfolio companies throughout their lifecycle. Kompas VC's investment strategy centers on three primary sectors: the built environment, manufacturing, and climate technology. They back innovative startups that aim to reduce carbon emissions, improve energy efficiency, and promote sustainable practices in construction and manufacturing. Their portfolio includes companies like CyanoCapture, which focuses on low-energy carbon capture technology, and Material Evolution, which produces low-carbon cement from industrial waste. The firm is driven by a mission to support the most talented entrepreneurs who are committed to creating a zero-emission, zero-waste building and manufacturing industry. Kompas VC also provides strategic guidance, mentorship, and access to a robust network to help their portfolio companies succeed in competitive markets.

Korify Capital, based in Basel, Switzerland, focuses on early and growth-stage investments in the biotech sector, particularly targeting longevity and mental health. Launched by Robin and Peter Lauber’s family office, Infinitas Capital, Korify Capital aims to drive forward breakthrough technologies that can extend healthy lifespan and address mental health issues. Notable investments include Alto Neuroscience, which uses AI-derived brain biomarkers to develop psychiatric treatments, and Cambrian Biopharma, which is pioneering therapeutics to lengthen healthspan by targeting the biological drivers of aging. Another significant investment is Gameto, which focuses on improving assisted fertility and tackling ovarian aging through cellular reprogramming. Korify Capital also invests in companies like Refoxy, which develops medicines to treat age-related diseases by modulating stress response pathways, and Rejuveron, a biotech firm aiming to transform aging-related scientific discoveries into practical treatments. These investments demonstrate Korify’s commitment to supporting innovative approaches in the biotech field, aiming to enhance longevity and overall health. The firm’s strategy involves leveraging its extensive venture capital network and deep expertise in biotech to support these transformative companies, helping them achieve significant milestones and growth.

Krane Ventures is a Vancouver, British Columbia-based venture capital firm investing at Technology Readiness Level 6 and above in deep tech, sustainability, and the AI-industrialized future. The firm backs founders building transformative companies across multiple technology frontiers, with an emphasis on companies that have moved past early research stages and demonstrated functional prototypes or commercial proof points. The portfolio of 12 companies spans AI, energy, fintech, SaaS, and biotech, investing primarily across Canada and the United States. Krane covers pre-seed and seed stage investments with check sizes in the $100,000 to $500,000 range. Despite a lean public footprint, the firm's portfolio includes several high-profile names that speak to strong deal-flow access within the Canadian deep-tech ecosystem. Cohere, the Canadian AI and natural language processing platform, is among the most prominent portfolio companies. Helion Energy, the nuclear fusion energy company, represents the firm's cleantech conviction. Other portfolio companies include Zafin (banking software platform) and Genomii (genomics). Additional investment activity spans fintech, marketing tech, machine learning, mining tech, and construction tech sectors. Krane provides portfolio companies with mentorship sessions and startup perks, and the firm's focus on TRL6-plus signals a preference for companies where the technical risk is largely resolved and the primary challenge is commercial execution. Limited public disclosure on fund size and team composition reflects a lean operation, but the quality of the portfolio — particularly Cohere and Helion — demonstrates access to top-tier founders at formative stages.

KTB Network, established in 1981 as one of South Korea's pioneering venture capital firms, has grown into a key player in the global investment landscape. Initially set up as a government-backed entity to promote tech-driven growth, it has expanded its reach across various sectors, including healthcare, fintech, edtech, robotics, and more. With headquarters in Seongnam, South Korea, KTB Network also operates internationally with offices in China, the U.S., and other regions. The firm primarily invests in early and growth-stage startups, with investment tickets ranging from $5 million to $10 million. KTB's diversified portfolio includes over 250 companies, and it has been involved in numerous successful IPOs both domestically and abroad, accounting for more than 10% of all Korean IPOs. This track record reflects KTB's ability to identify and nurture high-potential ventures, providing not only capital but also strategic support to help companies scale and succeed globally. KTB Network's investment philosophy emphasizes long-term partnerships, with a focus on sustainable growth. It engages in active value creation, assisting portfolio companies through business development, market expansion, and operational improvements. By aligning interests and maintaining strong compliance and governance standards, KTB Network continues to play a significant role in driving innovation and entrepreneurial success across Asia and beyond.

Kurma Partners is a prominent European venture capital firm based in Paris, specializing in healthcare and biotechnology investments. Founded in 2009, Kurma Partners has carved a niche in transforming cutting-edge scientific research into viable businesses. Their portfolio includes over 60 companies, with notable investments in Dynacure, Cardiologs, and IO Biotech. Focusing primarily on biotechnology, therapeutics, diagnostics, and health tech, Kurma Partners supports companies from early-stage seed funding to growth capital. They are particularly known for their deep collaboration with leading European research institutes, which helps them create startups based on groundbreaking scientific discoveries. This approach has resulted in the creation of more than 24 companies, many of which have become leaders in their fields. Geographically, Kurma Partners concentrates on Europe but has also made strategic investments in the United States. Their investment strategy includes both leading and participating in funding rounds, with typical investment sizes ranging from €1 million to €10 million, depending on the company's stage and needs. Kurma Partners' funds include the Kurma Biofund series and the Kurma Diagnostics funds, which emphasize innovative therapeutic and diagnostic solutions. The firm's leadership team boasts significant expertise, with key figures such as Thierry Laugel, Rémi Droller, and Sylvain Cascarino steering its strategic direction. They are actively involved in the portfolio companies, providing not just capital but also mentorship and industry connections. Kurma Partners is also committed to ESG principles, ensuring their investments align with ethical standards and contribute to sustainable development goals. For startups seeking investment, Kurma Partners recommends approaching them with a clear validation plan and leveraging their strong network of industry experts and entrepreneurs.

L'ATTITUDE Ventures is a $100M+ institutional venture capital firm focused exclusively on early-stage companies owned and led by U.S. Latino entrepreneurs. Recognizing the growing impact of Latino-led businesses on the U.S. economy, L'ATTITUDE Ventures aims to unlock the full potential of this entrepreneurial cohort by providing transformative capital and strategic connections. The firm supports startups from pre-seed to Series A across sectors such as technology, fintech, healthcare, and consumer products. Founded by Sol Trujillo and Gary Acosta in 2018, L'ATTITUDE Ventures operates with the goal of driving wealth creation within the U.S. Latino community, which represents 80% of net new businesses and contributes significantly to the U.S. economy. The firm’s investments are not just about financial backing; L'ATTITUDE provides active guidance in business development, fundraising, and leadership support, leveraging an extensive network of influential partners. L'ATTITUDE Ventures is particularly known for its annual "Match-Up" event, a pitch competition that connects Latino entrepreneurs with institutional investors, helping to fuel the growth of high-potential companies. The firm is based in San Diego and continues to expand its portfolio with innovative, scalable businesses that are poised for long-term success​.

L&S Venture Capital is a Seoul, South Korea-based venture capital firm founded in 2006, managing approximately 501.8 billion won, equivalent to roughly $400 million USD. The firm has a team of 15 including 6 partners, investing from incubation and seed stages through early and expansion rounds, with typical check sizes of $1 million to $5 million at Series A. L&S leads rounds and has one of the most impressive IPO track records among Korean venture firms, with 26 portfolio IPOs and 3 acquisitions across 90 total investments. The firm's investment focus spans semiconductors, materials, components and equipment, artificial intelligence, IoT, cloud computing, big data, mobile and network infrastructure, and e-healthcare. Notable IPO exits include INNOSPACE (space launch technology, KRX listing in July 2024 at a $293 million market capitalization), E8IGHT (KRX, $142 million market capitalization), SillaJen (oncolytic immunotherapy biopharmaceutical), and PharmAbcine (antibody therapeutics). The most notable acquisition was Panax Etec, sold to Dongwha Enterprise in August 2019 for $97.1 million. The most recent investment was AIRS at Series A in March 2025, with recent activity also including Align AI and Ettifos. L&S also invests in Israel alongside its primary focus on the Seoul, Gyeonggi, and Chungnam regions of Korea. L&S provides financial, business, and strategic support to portfolio companies across smart IT, green energy, fusion technology, and media content sectors. The firm's sustained 90-investment track record and 26-IPO exit history reflect a deep integration with the Korean capital markets ecosystem and a proven ability to guide technology companies through public listing processes.

La Famiglia VC is a European venture capital firm based in Berlin, Germany, that specializes in seed and growth-stage investments in technology companies. The firm focuses on startups that enable or disrupt large industries, particularly in sectors such as AI, machine learning, data, logistics, supply chains, and fintech. Notable portfolio companies include Personio, Forto, Deel, Stripe, and Applied Intuition. The team at La Famiglia is led by co-founder Jeannette zu Fürstenberg, who drives the fund's vision and leverages her extensive network in the tech ecosystem. Other key team members include Judith Dada, known for her expertise in data and machine learning-driven business models, and Reda Awad, who focuses on investments in France and has a passion for payment systems. La Famiglia's investment strategy involves providing not only capital but also access to a network of world-leading entrepreneurs and industry experts, enabling early market access and impactful partnerships for their portfolio companies. They aim to support startups that have the potential to transform significant industries through technological innovation.​

Lakehouse Ventures, a venture capital firm based in New York City, was founded in 2016 by John Neamonitis. The firm specializes in seed-stage investments, focusing on innovative, technology-enabled businesses that aim to improve everyday life. Lakehouse Ventures supports founder-led companies during their earliest stages, offering not only financial backing but also strategic resources and networking opportunities to help them grow and succeed. Notable investments in Lakehouse Ventures' portfolio include Rhino, a SaaS-driven security deposit insurance platform for renters; Mixlab, an internet-first brand offering customized drugs for pets; and Billie, a brand of hair removal products for women, which was acquired in 2021. Other significant investments are in Base, a provider of at-home blood testing; Courted, an app and SaaS-driven network for real estate professionals; and Kingdom Supercultures, a food ingredients processing company based in Brooklyn. Lakehouse Ventures has a strong track record with 44 investments and several successful exits, including the personal care brand Billie and financial services company Harvest. The firm's approach focuses on high-conviction investments, typically leading equity financing rounds with check sizes ranging from $1 million to $2 million.

Lansdowne Partners, founded in 1998 by Paul Ruddock and Steven Heinz, is a prominent investment management firm based in London. Initially known for its hedge fund strategies, Lansdowne has transitioned to focus more on long-only investment strategies. The firm has a notable history of significant investments and strategic shifts, particularly its recent move away from short-selling to concentrate on long-only funds. One of Lansdowne's major recent developments is the acquisition of CRUX Asset Management in 2023, expanding its capabilities in active equity management​​. The firm manages a variety of funds, including the Lansdowne Developed Markets Long-Only Fund and the Lansdowne Energy Dynamics Fund, which focuses on global renewable energy investments​. Lansdowne Partners' investment approach is rooted in rigorous fundamental research and a commitment to long-term performance. The firm is led by key figures such as Brian Heyworth, the current CEO, and Peter Davies, who heads the Developed Markets Strategy​​. This leadership team continues to guide Lansdowne through its evolving investment strategies and market conditions.

Launch Africa Ventures is a leading pan-African venture capital firm focused on addressing the funding gap for seed and pre-Series A startups across the continent. Founded in 2020 by Zachariah George and Janade du Plessis, Launch Africa has rapidly become one of the most active investors in the region. The firm has made significant investments in over 133 startups through its first fund, which raised $36.3 million by March 2022, and continues its momentum with a second fund that has invested $4.3 million into 16 startups across 11 African countries. Notable investments from Launch Africa include Bitmama, BFree, Chekkit, djamo, Gozem, Julaya, and Kuda. They focus on sectors such as fintech, logistics, health tech, and clean energy. Recent investments from their second fund feature startups like Servisor, Credit Circuit, and Shiprazor in South Africa; Lengo, Paps, and Solarbox in Senegal; Logistify and Octavia Carbon in Kenya; and Periculum and Kredete in Nigeria. Launch Africa's investment strategy emphasizes founder diversity, market potential, and geographical reach, supporting startups that have gone through renowned accelerator programs and display strong growth prospects. This approach not only helps in scaling these ventures but also contributes to the broader economic development of the African continent.

LaunchCapital, established in 2008, focuses on seed-stage investments and is backed by the Pritzker/Vlock Family Office. The firm has invested in over 200 companies, enabling entrepreneurs to build innovative businesses across various industries. Notable portfolio companies include Snapchat, Life360, and Formlabs, demonstrating their broad investment scope from consumer apps to advanced technology​​. LaunchCapital provides substantial support to its portfolio companies, emphasizing mentorship and strategic guidance. They typically invest during a company's first or second round of institutional funding and continue to support these companies through significant follow-on investments. Their approach is characterized by a commitment to milestones, capital efficiency, and a focus on developing both the entrepreneur and the business​​. With offices in Boston, New Haven, New York, and San Francisco, LaunchCapital maintains a national presence, ensuring they can support founders across the country. The firm's hands-on approach and strong network of advisors and entrepreneurs make it a valuable partner for startups looking to scale​.

Launchpad Venture Group is a prominent angel investment firm based in Boston, Massachusetts, focusing on early-stage technology and life science startups in the New England area. Since its inception in 2001, the firm has invested over $125 million in more than 150 startups, offering both financial support and human capital to foster growth and innovation. The firm’s portfolio includes a variety of sectors such as e-commerce, enterprise technology, healthcare, green technology, and education. Notable current investments include companies like ezCater, a corporate catering platform; Qstream, a mobile sales enablement and analytics tool; and RaySecur, which specializes in mail security through 3D scanning technology. Past successful exits include acquisitions of EnergySage by Schneider Electric and Localytics by Upland Software. Launchpad is renowned for its active angel network, providing startups with mentorship, strategic advice, and access to a wide range of industry connections. They focus on building long-term relationships with their portfolio companies, helping them scale and succeed in competitive markets​.

LAUNCHub Ventures is a leading early-stage venture capital firm based in Sofia, Bulgaria, focused on supporting startups across South-Eastern (SEE) and Central-Eastern (CEE) Europe. Since its inception in 2012, LAUNCHub has become a prominent player in the regional tech ecosystem, investing in pre-seed and seed-stage companies that aim to address large-scale problems with global solutions. The firm is currently investing out of its third fund, which has a size of €74 million. LAUNCHub typically writes initial checks ranging from €300,000 to €3 million and provides extensive strategic support to its portfolio companies, helping them prepare for larger rounds with top-tier investors. They are known for their hands-on approach, offering mentorship, access to a wide network of co-investors, and facilitating connections to potential clients. This has helped 75% of their portfolio companies secure follow-on funding, raising over €400 million in total. The firm’s portfolio includes successful companies like Quantive, a strategy execution platform; FintechOS, a no-code software provider for financial services; and Giraffe360, a proptech company specializing in 360-degree cameras. LAUNCHub’s commitment to sustainability is reflected in their ESG policies, ensuring that their investments align with responsible and ethical business practices. Their focus on innovation, combined with a robust regional network, makes them a key supporter of early-stage startups in SEE and CEE.

Lauxera Capital Partners is a healthcare-focused investment firm, specializing in growth-stage companies that are scientifically de-risked and have clear commercial pathways. Founded in 2020, the firm operates from Paris and San Francisco, with a focus on innovative healthcare sectors like medical devices, digital health, diagnostics, life sciences tools, and healthcare IT. They invest when startups have a proven revenue model and are ready to scale, contributing both capital and strategic expertise. Lauxera manages over €260 million through its Lauxera Growth I fund and typically invests between €300,000 and €3 million per startup. The firm is known for its hands-on approach, leveraging the operational experience of its team to support management in overcoming growth challenges and optimizing market adoption. Notable investments include Natural Cycles and Caresyntax, highlighting their commitment to cutting-edge health technologies​. Lauxera’s global perspective and strong European roots, combined with its healthcare expertise, make it a valuable partner for startups aiming to scale in large healthcare markets​.

LBBW Venture Capital (LBBW VC) is a Stuttgart-based venture capital firm founded in 1998 as an independent subsidiary of Landesbank Baden-Wurttemberg, one of Germany's largest state banks. The firm invests in early-stage disruptive IT and life science companies in the DACH region (Germany, Austria, and Switzerland), with initial ticket sizes of up to 3 million euros at seed and Series A stages. The team of seven includes two partners. Over its 18-plus-year track record the firm has invested in more than 60 companies, averaging approximately two new investments per year over the last decade. The tech team focuses on software-driven approaches within enterprise IT, IoT, Industry 4.0, AI and machine learning, and big data and analytics across industrial sectors. In life sciences, LBBW invests in drug development, diagnostics, medical devices, and healthcare IT. The firm leads rounds and has invested in 58 tracked companies. Recent investments in 2025 include Kipu Quantum (quantum computing, October 2025), Applyo-Jena (freeze-drying technology, Series A co-led with Bosch Ventures), and Blockbrain (AI-based knowledge management). The portfolio has achieved notable exits including 2 IPOs, 1 unicorn, and 11 acquisitions, with key exits including ESI Group, Oxid eSales, MTM Laboratories, and a stake sold in September 2022. Investing on behalf of LBBW enables the firm to take a long-term view on early innovation — particularly valuable for deep tech and life science companies that require patient capital through extended development cycles. LBBW VC is a member of BVK, the German Private Equity and Venture Capital Association, and leverages the parent bank's industrial and corporate relationships to open commercial doors for portfolio companies across the DACH manufacturing and technology ecosystem.

LDV Capital, founded in 2012 and based in New York, is a venture capital firm specializing in early-stage investments in visual technology and artificial intelligence. The firm focuses on backing deep technical teams across North America and Europe that leverage computer vision, machine learning, and AI to analyze visual data. LDV Capital's investments span various industries, including healthcare, agriculture, manufacturing, and content creation. The firm has a robust network of computer vision experts, serial entrepreneurs, and technical advisors, which it uses to support its portfolio companies. Notable investments include Clarifai, Uizard, Synthesia, and Ezra, reflecting LDV's commitment to innovative visual tech solutions. LDV Capital's founder and General Partner, Evan Nisselson, brings extensive experience as a serial entrepreneur and digital media expert. LDV Capital hosts an annual summit dedicated to visual technologies and maintains a strong community through monthly dinners and networking events, fostering collaboration and innovation within its portfolio and the broader tech ecosystem. The firm recently closed its fourth fund at $31 million, continuing its mission to support groundbreaking visual technology startups.

Leaps by Bayer, founded in 2015, is Bayer AG's strategic impact investment unit focusing on transformative biotechnologies in health and agriculture. Since its inception, Leaps by Bayer has invested over $1.9 billion in more than 60 ventures, targeting significant challenges through ten key "leaps" designed to address pressing global issues. Key investments include Recursion Pharmaceuticals, which focuses on drug discovery using AI, and BlueRock Therapeutics, a company specializing in cell therapy. These investments align with their strategic goals such as curing genetic diseases, developing sustainable organ and tissue replacements, and reducing the environmental impact of agriculture. Leaps by Bayer's portfolio companies operate autonomously, but benefit from Bayer’s active incubation model, which provides resources and strategic guidance. This approach helps them focus on long-term, high-impact results rather than short-term gains. Leaps by Bayer also collaborates globally with partners in industry, academia, and civil society to drive these innovations forward.

Leawood Venture Capital, established in 2016, is an early-stage investment firm based in Leawood, Kansas. The firm is dedicated to backing disruptive technology companies, with a particular focus on sectors such as artificial intelligence, data analytics, cybersecurity, fintech, and edge computing. Leawood's approach is highly strategic, leveraging its team’s deep experience and national network to help portfolio companies scale and succeed. Typically investing between $2 to $4 million, Leawood often leads or co-leads investment rounds in high-potential companies. The firm has made notable investments in businesses like Sorcero, which develops AI solutions for the life sciences industry, and InsightRX, a leader in precision medicine using machine learning and clinical algorithms to optimize patient treatment. Other portfolio highlights include companies in areas like telecommunications, predictive analytics, and AI-driven customer experience platforms. Leawood’s founding partners, Karl Gemperli and Brendan Fallis, bring decades of operational and entrepreneurial expertise. Gemperli, with a background in industrial IoT and wireless technologies, and Fallis, a former executive at Verizon Wireless, offer invaluable experience in scaling technology ventures. Alongside managing director Todd Daniels and a seasoned investment committee, the team provides hands-on support to startups, from business development to financial operations. With a focus on creating long-term value, Leawood Venture Capital continues to be a key player in supporting early-stage tech companies across the U.S., using their industry knowledge and vast networks to drive innovation and growth.

Legend Capital, established in 2001, is a leading venture capital and private equity firm in China. The firm focuses on early-stage and growth-stage investments, managing over $10 billion in commitments. With a strong presence in Beijing, Shanghai, Shenzhen, Hong Kong, Seoul, and Singapore, Legend Capital has invested in around 600 companies across various sectors. Some of their notable investments include Pony.ai, which focuses on autonomous driving technology, and Beijing ESWIN Technology Group, a key player in semiconductor products and services. Legend Capital also supports companies like ZongmuTech in autonomous driving and Atour, a lifestyle accommodation brand. Additionally, they have invested in prominent companies like Bilibili, a leading video community, and Tuhu, an automotive consumer service platform. Legend Capital has a significant footprint in the life sciences sector, with portfolio companies like Recbio, a novel vaccines company, and Pharmaron, a leading contract research organization. Their investments are characterized by a focus on innovative technologies and solutions that drive industry advancements and address critical needs in the market. The firm is committed to providing comprehensive support to its portfolio companies, including governance, business strategy, R&D resources, and financial backing, helping them to scale and achieve long-term success.

Lerer Hippeau is a prominent seed-stage venture capital firm based in New York City. Founded in 2010, it has built a strong reputation for backing early-stage startups with transformative potential. The firm has invested in over 400 companies, including notable successes like Warby Parker, Allbirds, BuzzFeed, Oscar Health, and ClassDojo. Their portfolio spans various sectors, with significant investments in consumer products, enterprise software, healthcare, fintech, and media. Lerer Hippeau's investment strategy focuses on partnering with innovative founders and providing extensive support to help them grow. They typically invest in seed and early-stage rounds but also participate in follow-on investments to support the continued growth of their portfolio companies. The firm is known for its hands-on approach and deep network, which they leverage to help startups scale. Key figures at Lerer Hippeau include managing partners like Ben Lerer, Eric Hippeau, and Graham Brown, who bring a wealth of experience and industry insight. The firm is recognized for fostering a collaborative and founder-friendly culture, making it a preferred choice for many early-stage entrepreneurs looking for more than just capital. Lerer Hippeau’s notable unicorns include SeatGeek, ClassDojo, and Genies, among others. The firm has also seen several successful IPOs, including companies like Allbirds and Warby Parker, further establishing its reputation as a leading early-stage investor. For startups aiming to connect with Lerer Hippeau, it's beneficial to showcase innovative solutions with strong market potential, aligning with the firm’s focus on supporting transformative and high-growth ventures​.

LetsVenture, established in 2013, is a prominent platform in India's private market investment ecosystem, focusing on early-stage startups. The platform has facilitated over 900 investments, raising more than $250 million for startups, and is backed by notable figures like Ratan Tata and Mohandas Pai. LetsVenture supports a wide array of sectors including e-commerce, software, healthcare, and food and beverage. The platform's investment strategy includes seed and series A rounds, with significant investments in companies like Testbook.com, Innov8 Coworking, and Scripbox. LetsVenture operates through various verticals such as LetsVenture Early Stage, which connects investors with disruptive early-stage startups, and LetsVenture Debt, providing loans to startups for growth. They also offer trica equity, a solution for managing equity, cap tables, and ESOPs. LetsVenture has a robust network of over 20,000 investors and 500 family offices and VCs, making it a vital player in the Indian startup ecosystem. The platform also organizes the annual LetsIgnite event, one of India’s largest conclaves for startup investors, fostering connections and growth within the community​.

Level Up Ventures is a mission-driven venture capital firm based in New York that focuses on closing the racial wealth gap by investing in high-growth startups led by Black and Latino founders. Founded in 2021 and backed by Hearst, the firm offers $300,000 in pre-seed or seed funding along with strategic support and services. They concentrate on tech and tech-enabled companies across various sectors, with a clear emphasis on diversity and inclusivity in their portfolio companies. Level Up Ventures aims to help founders scale through access to Hearst's resources, mentorship, and networks. The firm seeks startups that have validated solutions, demonstrated market traction, and are committed to building diverse teams. Some of the notable companies in their portfolio include Options MD, a healthcare SaaS platform for treatment-resistant depression, and Sunthetics, which uses AI to enhance the development of sustainable materials. They avoid investing in biotech, hardware, or capital-intensive projects. By providing more than just capital, Level Up Ventures combines financial investment with operational expertise, making it a key player in promoting underrepresented founders in the tech space.

Lewis & Clark Ventures is an early-stage venture capital firm based in St. Louis, Missouri, specializing in B2B software investments. Founded by former founders and operators, the firm leverages its team's extensive entrepreneurial experience to partner with dynamic founders aiming to build successful companies. They focus on late seed to Series A investments, typically ranging from $2 million to $3 million per initial investment. The firm's portfolio includes innovative companies like Beam Benefits, Benson Hill, and GreenLight Biosciences. Lewis & Clark Ventures is known for its hands-on approach, often taking board seats and providing strategic, technical, and commercial support to help their portfolio companies scale effectively. Their investment strategy targets high-growth opportunities in overlooked geographies, emphasizing the importance of founder vision, team strength, and market potential. The firm values transparency, smart growth, and long-term partnerships, aiming to support founders not just with capital but also with mentorship and access to their extensive networks.

Lexi Ventures is a Menlo Park-based venture capital firm founded in 2023 by Jonah Probell, focused exclusively on seed-stage genetic engineering startups. Branded as Genetic Engineering Capital, the firm invests in US-based companies building around DNA, RNA, cells, and omics technologies. Probell brings 25 years of startup experience across seven companies in founder, executive, and engineering roles, having achieved two IPOs, 16 granted patents, and authored two books. The firm's thesis is that the genetic engineering revolution will be among the most value-creating venture categories of the next decade, as biology has transitioned from science to engineering. Lexi invests $50,000 to $500,000 with a sweet spot of $250,000, deploying approximately 10 investments annually and ranking among the top 20 VC funds active in the gene tech niche. The portfolio of 11-plus companies includes Kopra Bio (T-cell immunotherapy for solid tumors, most recent investment October 2025), ParcelBio (programmable mRNA delivery), KiraGen Bio (high-fidelity CRISPR tools, raised $2.5 million, Harvard Innovation Lab), QUiCKR Bio (gene editing quality control), Melio (rapid newborn pathogen diagnostics), AlkaLi Labs (biomining with microbes for critical minerals), Glyphic Bio (single-molecule protein sequencing), Syntensor (AI simulation for clinical trials), TippingPoint (precision genetic medicines for rare pediatric diseases), Taxa (bio-engineered probiotic skincare), and Crank Bio (RNA-based antisense therapeutics for rare diseases). Co-investors include IndieBio/SOSV and Activate Global. Lexi Ventures participates in the BIO Investor Forum and operates as a specialist conviction fund, aiming to be the first check for founders building at the frontier of genetic engineering. The firm's narrow focus gives it genuine domain depth — Probell evaluates deals not as a financial generalist but as someone who has built and scaled scientific companies from the lab bench outward.

LG Technology Ventures, founded in 2018 and based in Santa Clara, California, is the corporate venture capital arm of LG Group. The firm focuses on investing in early-stage companies across various sectors, including artificial intelligence, information technology, automotive, life sciences, and energy. With over $400 million in managed assets, LG Technology Ventures aims to drive innovation and growth by partnering with promising startups. Their portfolio includes notable investments in companies like H2O.ai, which offers an open-source machine learning platform; The Sandbox, a virtual metaverse game; and Moloco, which provides AI-enabled mobile DSP software. They have also invested in Element Energy, a battery technology company, and Eatron Technologies, specializing in AI for automotive and electric vehicles​​. The team at LG Technology Ventures consists of experienced investors, technologists, and industry experts, led by Dong-Su Kim, Ph.D., who serves as the CEO. The firm is known for its strategic approach, often leading investment rounds and providing substantial support to its portfolio companies to help them scale and succeed globally.​

Libertad Ventures is the Mossad's Technological Innovation Fund, established in June 2017 as the strategic investment arm of the Israel Security and Intelligence Service. Libertad invests in breakthrough technologies using a unique equity-free model: the fund provides grants of up to NIS 2 million (approximately $580,000) per startup with no equity stake, no share ownership, no IP restrictions, and no royalty repayment. In return, the Mossad receives a non-commercial, non-exclusive license to use the developed intellectual property. The fund operates with an annual budget of approximately NIS 10 million ($2.9 million), typically funding 5 startups per year, and has completed over 30 deals since 2017. Libertad's investment scope covers more than 16 technology domains: fintech, robotics, data science, drones, personality profiling, big data, energy harvesting, natural language processing, voice analysis, AI, 3D printing and scanning, blockchain, machine learning, synthetic biology, smart city technology, and online privacy. The fund leads its supported projects and allocates dedicated teams to each portfolio company, maintaining collaborative working relationships throughout the R&D process. Portfolio company names are not publicly disclosed due to the classified nature of the parent organization. The fund accepts hundreds of applications annually and has expanded its scope over time to accommodate emerging fields. Libertad is analogous to the CIA's In-Q-Tel in its role as an intelligence agency's technology investment arm, but operates with a fundamentally different economic model. The equity-free grant structure removes the commercialization friction that typically constrains deep-tech startups, allowing founders to retain full ownership while developing technologies that address national security and intelligence requirements.

Libertus Capital is a London-based venture capital firm, founded in 2017 by Pamir Gelenbe. The firm specializes in investing in early-stage ventures and protocols that focus on enhancing freedom, privacy, and trust, particularly within the blockchain, cryptocurrency, and Web3 sectors. With a global investment outlook, Libertus Capital targets companies across North America, Europe, and Asia. The firm has built a diverse portfolio, backing companies like Livepeer, a decentralized video streaming platform; CoinList, a popular token sale platform; and Kraken, a leading cryptocurrency exchange. Other notable investments include infrastructure and software projects such as Sky Mavis, the developer behind Axie Infinity, and POAP, an NFT-based event engagement tool. These investments underscore Libertus Capital's commitment to supporting projects that leverage decentralized technologies to offer more secure and user-centric solutions. Libertus Capital prefers to invest in seed to Series B rounds, with typical ticket sizes ranging from $5 million to $10 million. They take a hands-on approach, offering not just capital but also strategic guidance and industry expertise to help startups scale. The firm is also actively involved in building long-term value, with exit strategies that include IPOs, mergers, and strategic sales, aligning with their focus on sustainable growth within the rapidly evolving tech landscape.

Lightspeed Venture Partners is a prominent global venture capital firm that focuses on seed, early, and growth-stage investments across various sectors, including enterprise, fintech, consumer, and healthcare. Established in 2000, Lightspeed has raised significant capital over the years, including $4.2 billion in 2020 across three funds: an $890 million early-stage fund, a $1.83 billion growth fund, and a $1.5 billion opportunity fund. The firm has a robust portfolio with notable investments in companies like Snap, Nutanix, and Zscaler, reflecting its success in backing high-growth tech startups. Lightspeed has also been instrumental in the growth of other leading companies such as Affirm, MuleSoft, and The Honest Company. Their global reach includes offices in the United States, Israel, India, China, Southeast Asia, and Europe, enabling them to support entrepreneurs worldwide. Lightspeed's investment philosophy centers on deep engagement with their portfolio companies, offering not only capital but also strategic guidance and operational support. This hands-on approach helps startups navigate the challenges of scaling and achieving market leadership. Their commitment to building long-term relationships with founders and their focus on creating enduring companies sets them apart in the venture capital landscape.

Life.SREDA is a Singapore-based venture capital firm, established in 2012, that focuses exclusively on fintech investments. It was one of the first non-corporate VC funds to specialize in fintech, making significant strides in shaping the fintech landscape across Asia and globally. The firm has raised two major funds: Life.SREDA I ($40 million) and Life.SREDA II Asia ($100 million), which have enabled investments in over 20 fintech startups. These include well-known names like Simple, Moven, and Fidor, which are recognized for disrupting traditional financial services. Life.SREDA also manages the BB Fund, a blockchain-focused investment vehicle launched in 2016, further expanding its reach into emerging technologies. The fund targets companies involved in blockchain and cryptocurrency, reflecting its commitment to staying at the forefront of financial innovation. The firm's investment strategy focuses on early-stage companies in the fintech space, helping to nurture them through their growth stages and leading to multiple successful exits, such as Allset Technologies and Life Pay. Life.SREDA has built a reputation as a major player in the Asian fintech ecosystem and continues to invest in companies that are transforming financial services through technology.

LifeForce Capital, founded in 2015 and based in San Francisco, specializes in investing in healthcare companies that are advancing care delivery through innovative technologies and new care models. They focus on digital health startups that enable new therapeutic development and efficient care delivery. Some of their notable investments include Notable Labs, which leverages AI for precision oncology, Clover Health, a technology-driven health insurance company, and One Medical, a membership-based primary care platform. LifeForce Capital targets early to late-stage ventures, with a typical investment ranging from seed to Series B. They emphasize a software-first approach, aiming to drive a paradigm shift in healthcare. Their strategy involves supporting companies that offer scalable solutions with significant potential for improving patient outcomes and healthcare efficiency. The firm has a solid track record with successful exits such as Cricket Health and TARA Biosystems. The investment team, led by founder John Noonan, includes experts like Dr. Dora Hughes and Nathaniel Bays, who bring extensive experience in healthcare investment and operations. For entrepreneurs, LifeForce Capital looks for groundbreaking innovations that align with their mission to reshape healthcare. Startups are advised to present clear, impactful solutions that demonstrate potential for significant advancements in care delivery and therapeutic development​.

Lightbank, founded in 2010 by Brad Keywell and Eric Lefkofsky, is a venture capital firm based in Chicago, Illinois. The firm focuses on early-stage investments, typically in pre-seed, seed, and Series A rounds, with initial check sizes ranging from $250,000 to $5 million. Lightbank has built a diverse portfolio across various sectors, including consumer, enterprise, healthcare, fintech, and climate tech. Among Lightbank's most notable investments are Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare; Sprout Social, a social media management and marketing platform that went public in 2019; Udemy, an online learning and teaching marketplace with over 155,000 courses; Fiverr, an online marketplace for freelance services, which also went public; and Ovia Health, a women's health and family health company acquired by Labcorp. Lightbank has made a total of 219 investments and has had 91 exits, demonstrating a strong track record of successful investments and strategic exits. The firm's latest investments include companies like Aropha and Ohana Subleasing Co., continuing their commitment to innovative and high-potential startups.

Lightrock is a global private equity firm that focuses on investing in sustainable businesses led by purpose-driven entrepreneurs. The firm aims to drive systemic change at scale through innovation, aligning its investments with impact themes such as "people," "planet," and "productivity/tech for good." Founded under the umbrella of LGT, Lightrock is committed to creating positive societal and environmental returns alongside financial gains​. Lightrock's diverse portfolio includes over 60 high-growth companies worldwide. Notable investments include Infarm, a rapidly growing urban farming network; PharmEasy, a leading omni-channel healthcare platform in India; and M-Kopa, a pioneer in pay-as-you-go solar energy services for off-grid customers in East Africa​. The firm actively supports its portfolio companies, often taking board positions to guide their dynamic growth and expansion. Headquartered in London, Lightrock operates globally with a team of more than 55 investment professionals across four continents, encompassing extensive experience in impact investing, leadership, and entrepreneurship. The firm is led by CEO Pal Erik Sjatil, the former Managing Partner of McKinsey & Company Europe​.

Lightship Capital is a venture capital firm with a distinct mission to empower and invest in underrepresented entrepreneurs. Based in Cincinnati, Ohio, Lightship specifically targets startups led by BIPOC (Black, Indigenous, and People of Color), women, LGBTQ+ individuals, and people with disabilities. Their investments span across the Midwest and South, purposefully avoiding oversaturated markets like Silicon Valley, New York, and Boston. The fund’s industry focus includes sectors such as Consumer Packaged Goods (CPG), E-commerce, Sustainability, Artificial Intelligence (AI), and Health Tech. Notable investments include companies like Healthy Roots Dolls, Vyrill, and ProovTest, which exemplify their commitment to supporting high-growth, impactful businesses. Lightship typically invests at the pre-seed to Series A stages, with an average check size of around $2 million. They are known for actively leading rounds and bringing in Executives-in-Residence with experience from major corporations like Procter & Gamble and Cincinnati Children’s Hospital to support portfolio companies. The firm is led by General Partners Candice Matthews Brackeen and Brian Brackeen, who bring extensive experience in fund management and technology. Their approach to sourcing deals emphasizes building relationships within underrepresented communities and fostering long-term success through hands-on mentorship and strategic guidance. For startups looking to connect with Lightship, aligning with their mission to drive systemic change in the venture capital landscape is crucial.

Lightspeed Venture Partners, founded in 2000, is a prominent global venture capital firm based in Menlo Park, California. The firm specializes in multi-stage investments, supporting companies from seed to growth stages. Lightspeed's investment focus spans several sectors, including enterprise, consumer, fintech, and healthcare. Some of Lightspeed's notable investments include Snapchat, Affirm, and Rubrik. Snapchat, a popular social media platform, went public in 2017, marking a significant success for the firm. Affirm, a financial technology company, also achieved a successful IPO in 2021. Rubrik, a leader in cloud data management, is another key company in their portfolio that highlights Lightspeed's focus on disruptive technology. Lightspeed Venture Partners has raised substantial funds over the years to support its diverse portfolio. In 2020, the firm raised $4.2 billion across three funds: an early-stage venture fund, a growth fund for later-stage investments, and an opportunity fund for doubling down on successful investments. The firm's philosophy centers on deep commitment and collaboration with founders, providing not just capital but also strategic guidance and support to help build enduring companies. With a global presence and a history of backing innovative companies, Lightspeed continues to be a key player in the venture capital landscape.

Lightspeed Venture Partners is a prominent venture capital firm based in Menlo Park, California. Established in 2000, Lightspeed has a rich history of investing in a wide array of sectors including enterprise, consumer, fintech, and healthcare. The firm is known for its deep commitment to supporting companies from seed stage through growth stage. Lightspeed's portfolio includes several high-profile companies. They were early investors in Snapchat, Nutanix, MuleSoft, and AppDynamics, all of which have become significant players in their respective industries. Other notable investments include Affirm, Nest, and Ripple, demonstrating Lightspeed's diverse investment strategy and success across various markets​​. In 2020, Lightspeed raised $4.2 billion across three funds to continue supporting early-stage ventures and growth-stage companies. Their investment philosophy focuses on building strong, enduring companies with a hands-on approach, helping founders navigate the complexities of scaling their businesses​​. With a global presence, Lightspeed operates in several countries including the United States, Israel, India, and China. Their international portfolio reflects their ability to identify and nurture innovative companies worldwide.

Lightstone Ventures, founded in 2012, is a venture capital firm that focuses on early-stage investments in the life sciences sector. The firm is based in Menlo Park, California, with additional offices in Boston and Dublin. Lightstone Ventures has a strong track record of investing in biopharmaceutical and medical device companies. Notable investments by Lightstone Ventures include companies such as Reprieve Cardiovascular, which focuses on innovative treatments for heart failure, and Carrick Therapeutics, a biopharmaceutical company developing treatments for cancer. Another significant investment is in Catamaran Bio, which is advancing cell therapies for cancer. The firm recently closed its third fund at $375 million, which will be used to support early-stage companies developing high-impact therapeutics and technologies. Lightstone Ventures' investment strategy emphasizes translating novel scientific breakthroughs into clinically and commercially meaningful therapies. This approach has resulted in successful exits, such as Ra Pharmaceuticals and Disarm Therapeutics, highlighting their ability to nurture companies from inception to market success.

Lilly Asia Ventures (LAV) is a Shanghai-based biomedical venture capital firm founded in 2008 as the corporate venture arm of Eli Lilly before becoming fully independent in 2011, when it began raising third-party capital with Fund III. Headquartered in Shanghai with offices in Hong Kong and Palo Alto, LAV now manages approximately $4.5 billion in assets across seven funds. Fund VI closed at $1.35 billion in 2021, followed by Fund VII, which reached its $700 million hard cap. Managing Partner Yi Shi has led the firm since its founding, guiding its evolution from a corporate subsidiary into one of Asia's largest independent biomedical venture franchises. LAV invests globally across the full biomedical spectrum — from seed stage to publicly traded companies — in biopharmaceuticals, human therapeutics, medical devices, and diagnostics. The firm leads rounds and has made 326 total investments, achieving 54 portfolio exits. Among the most notable are NASDAQ IPOs for ArriVent, which reached a $575 million market cap in January 2024, and Alector, with a $1.3 billion market cap. Insilico Medicine became LAV's latest unicorn in 2025, exiting in December 2025 just three years after LAV's initial investment. Recent 2025 deals include StairMed Technology, Rona Therapeutics, EnChannel Medical, and a co-led $100 million Series C for Pulnova Medical. LAV's stated vision is to be the trusted partner for exceptional entrepreneurs seeking smart capital to build companies developing breakthrough health products. The firm brings deep scientific networks across Asia and North America, providing portfolio companies with access to clinical development expertise, regulatory knowledge, and global licensing relationships that are particularly valuable when bridging Asian and Western healthcare markets.

Lilly Ventures is the corporate venture capital arm of Eli Lilly and Company, based in Indianapolis, Indiana, and responsible for life science investing across North America and Europe. The fund manages approximately $200 million and operates as a therapeutically agnostic investor, backing companies from early to expansion stage across biotechnology, healthcare IT, and medical technology. It leads rounds and maintains a team of five professionals dedicated to identifying companies that can advance Lilly's drug discovery pipeline while also generating strong financial returns. In January 2025, Eli Lilly announced a landmark $500 million partnership with Andreessen Horowitz to create a new AI-focused biotech venture fund, signaling a major push into AI-driven drug development. The fund has made 84 investments and achieved an exceptional exit record of 36 exits, including 8 NASDAQ IPOs: BioAge Labs reached a $615 million market cap in September 2024, Kymeratx achieved an $863 million market cap, and Coherus Biosciences, Sutro Biopharma, and Protagonist Therapeutics have also gone public. The portfolio has also seen 19 acquisitions. Active portfolio companies include Insilico Medicine, an AI drug discovery firm that received Lilly Ventures' most recent investment in June 2025, alongside basys.ai and Evox Therapeutics. The fund also separately manages a $300 million Social Impact Venture Capital Portfolio targeting investments with measurable patient and societal benefit. Lilly Ventures operates as part of a broader Eli Lilly innovation ecosystem that includes Lilly Gateway Labs and Lilly ExploR&D, allowing portfolio companies to access laboratory infrastructure, scientific talent, and Lilly's global clinical and commercial networks. The fund's strategic alignment with Lilly's therapeutic priorities gives portfolio companies meaningful potential pathways to partnership and acquisition.

Linear Venture, also known as Linear Capital, is a Shanghai-based early-stage venture capital firm founded in 2014 by Harry Wang — a founding employee of Facebook — and Michael Zhang, a former JD.com and Alibaba Tmall executive. The firm focuses on frontier technology applications, with core investment sectors spanning AI software and applications, AI hardware and embodied intelligence, robotics, new energy and materials, and innovative biomedicine. Linear manages over $2 billion across ten funds, with a combined portfolio valuation of approximately $30 billion and a team that has grown to 23 members with three partners. The firm leads investments from angel through Series A stages, writing checks of $1 million to $10 million per project, and has backed over 170 companies — including 6 unicorns. The most prominent exit is Horizon Robotics, which IPO'd on the Hong Kong Stock Exchange in October 2024 at a $6.69 billion market cap. Other notable exits include Baixing, which listed on the Shanghai Stock Exchange at a $1.34 billion market cap, and the acquisitions of Agile Robots and Dianping. Additional portfolio companies include Tezign, Kujiale, and Rino.ai. Linear made 8 investments in 2024 and continued into 2025 with investments in Final Round AI and Shanghai Weijian Technology. Linear invests across China, Silicon Valley, and Southeast Asia, giving its portfolio companies access to both deep Chinese tech manufacturing ecosystems and global distribution channels. The firm's dual expertise in software applications and hardware manufacturing — particularly in embodied intelligence and robotics — positions it as one of the most active Chinese early-stage technology investors bridging Asian industrial capabilities with global markets.

LionBird, founded in 2012 and based in Tel Aviv and Chicago, focuses on early-stage investments in digital health companies. The firm targets startups that are leveraging technology to innovate and improve healthcare delivery and outcomes. Their diverse portfolio includes companies such as Ovia Health, a leader in family health solutions; Marqeta, a modern card issuing platform; and Bizzabo, an event management software company. LionBird has achieved notable exits including Ovia Health and Marqeta, which underline their strategic investment approach and successful track record. LionBird recently closed its third fund at $85 million, indicating strong support from institutional investors like the Healthcare of Ontario Pension Plan (HOOPP). This fund is set to invest in 15 to 20 early-stage companies within the digital health sector, reinforcing their commitment to transforming healthcare through technology. The firm is co-founded by Edward Michael JD, Chaim Friedman, and Jonathan Friedman, who bring extensive experience and a strong network to support their portfolio companies. LionBird aims to provide more than just capital, offering strategic guidance and resources to help startups navigate the complexities of the healthcare industry and achieve market fit.

Lionheart Ventures is a venture capital firm based in San Francisco, focused on mitigating civilizational risks through investments in transformative technologies. They primarily target areas like advanced artificial intelligence and frontier mental health technologies. The firm is guided by the belief that addressing these sectors can significantly impact humanity while generating attractive returns for investors. Lionheart Ventures' notable investments include companies like Anthropic, which specializes in developing general AI systems with an emphasis on responsible usage, and Calm, a global health and wellness app aimed at improving mental health through meditation and relaxation tools. Other significant investments are in Beam, a company focused on urban mobility solutions, and Charm Industrial, which works on carbon removal technologies. The firm is led by founders with extensive experience in venture capital and entrepreneurship, ensuring a deep understanding of the challenges and opportunities faced by startups. Their advisory team includes experts in AI safety, psychedelics, and mental health, such as Dr. Joseph Barsuglia and Allison Duettmann, who provide strategic guidance to portfolio companies. For startups looking to engage with Lionheart Ventures, it is essential to align with their mission of developing technologies that can mitigate existential risks and have a meaningful impact on humanity.

Liquid 2 Ventures, founded in 2015 by Joe Montana, Mike Miller, and Michael Ma, is a San Francisco-based venture capital firm specializing in seed-stage investments. The firm focuses on technology startups, aiming to provide early-stage companies with the capital and guidance needed to grow and succeed. Liquid 2 Ventures has made over 400 investments across various sectors, with notable companies including Athelas, Nurx, and Hyperplane AI​​. Liquid 2 Ventures employs a hands-on approach to investing, leveraging the expertise of its founding partners and a strong network of co-investors, including Y Combinator and Soma Capital. The firm's investment strategy centers around identifying innovative technology solutions and supporting them from their earliest stages. Recent investments include companies like Battlesnake, Overjet, and Pry Financials, which showcase their diverse portfolio spanning artificial intelligence, healthcare, and fintech​. For startups seeking to engage with Liquid 2 Ventures, the firm offers substantial support beyond just funding, focusing on building lasting companies through experience, community, and capital. Their commitment to fostering innovation makes them a valuable partner for early-stage technology ventures looking to make a significant impact.

Litani Ventures is a family office established by Peter Rahal, the founder of RXBAR, and is based in Chicago, Illinois, with an additional office in Miami, Florida. Founded in 2018, Litani Ventures focuses on early-stage investments, particularly in consumer products, food tech, and sustainability. The firm leverages Rahal's entrepreneurial background to invest in companies that have the potential to disrupt traditional industries. Litani Ventures operates with a hands-on approach, working closely with founders to provide strategic guidance and operational support. The firm’s investment portfolio includes a variety of innovative companies, such as Cove, a biodegradable materials company, and Zymochem, a biotechnology firm. Litani Ventures has been actively involved in over 66 investments, highlighting its commitment to fostering the growth of promising startups. In addition to direct investments, Litani Ventures is known for its involvement in successful exits, including high-profile companies like Dr. Squatch and Sprout Social. The firm continues to seek new investment opportunities, particularly in areas where it can have a meaningful impact​.

LocalGlobe, founded by Robin and Saul Klein in 1999, is a leading venture capital firm based in London. The firm focuses on seed and early-stage investments, typically investing $0-1 million. LocalGlobe has built a strong reputation for supporting startups from their inception to successful Series A rounds, often within 15 to 18 months. LocalGlobe is known for its hands-on approach, leveraging a network of industry experts and mentors to help portfolio companies navigate early-stage challenges. The firm looks for founders with a strong vision and passion for their industry, prioritizing solutions that address significant real-world problems. This strategy has led to investments in some of the most transformative companies, such as fintech giants, digital banking solutions, and innovative technology firms. Their focus is primarily on the UK market, deploying about 80% of their capital locally. This commitment to nurturing local talent has solidified their position as one of the most influential seed investors in Europe. LocalGlobe's approach and strategic investments have significantly impacted the global startup ecosystem, making them a crucial player in the venture capital landscape.

Longbow Capital is a Canadian private equity firm focused on investing in energy, power, and infrastructure sectors, with a strong emphasis on energy transition technologies. With over $1.5 billion in assets under management, Longbow has a track record of over 150 high-growth investments. They prioritize companies working towards efficient and environmentally responsible energy solutions, including clean energy, waste-to-power innovations, and advanced energy tech. Longbow’s investment strategy centers on both control and strategic minority positions in companies that are ready to scale. Their Energy Transition Fund is specifically geared toward businesses that capitalize on the global shift toward greener energy, such as Clir Renewables (AI-driven renewable energy software) and Arcus Power (predictive analytics for peak electricity costs). The firm tends to back experienced entrepreneurs with a proven customer base and strong product-market fit​. Headquartered in Calgary, Longbow is led by Managing Directors Larry and Tyson Birchall, with a deep bench of energy investment professionals. The firm’s focus on energy transition makes them a key player in the transformation of how energy is produced and consumed globally​.

Longbow Capital is a UK-based venture capital firm that has been investing in the healthcare, life sciences, and well-being sectors since its founding in 2004. Headquartered in Norwich, the firm primarily focuses on unquoted UK companies with strong growth potential. Longbow Capital specializes in identifying investment opportunities that can deliver exceptional returns for its high-net-worth and professional clients. With a proven track record in both early and late-stage investments, Longbow is particularly interested in innovative healthcare technologies and life sciences, as well as companies that align with the growing well-being industry. The firm's portfolio includes standout companies such as Calon Cardio-Technology and Destiny Pharma, which have progressed through clinical trials and even to IPOs, reflecting Longbow’s ability to back transformative ventures. Longbow is also actively involved in fostering partnerships with innovation hubs like the Boots Centre for Innovation, a collaboration aimed at bringing cutting-edge health and well-being products to market. This initiative, based in Swansea, provides a pathway for early-stage companies and inventors to scale their products within established retail networks, ensuring greater market access. A key aspect of Longbow’s investment strategy is its focus on tax-efficient investment vehicles such as the Enterprise Investment Scheme (EIS) and Business Property Relief (BPR). These schemes offer UK investors significant tax relief on their investments, including income tax, capital gains tax, and inheritance tax benefits. This tax-efficient approach, combined with the firm's deep sector expertise, positions Longbow as a leading investor in the UK’s dynamic healthcare and life sciences landscape​.